WebDoctor Encyclopedia

Invasive carcinoma

HER2-positive breast cancer

HER2-positive breast cancer overexpresses the HER2 receptor. This entry covers testing, anti-HER2 drugs, and how treatment has changed outcomes.

Medically reviewed Last reviewed October 21, 2026

Overview

HER2-positive breast cancer is a distinct molecular subtype of breast carcinoma characterized by the overexpression of the Human Epidermal Growth Factor Receptor 2 (HER2) protein or amplification of the ERBB2 gene. Accounting for approximately 15–20% of all invasive breast cancers, this subtype is biologically aggressive but uniquely amenable to targeted therapies that have dramatically altered its natural history.

Historically associated with a poorer prognosis compared to hormone receptor-positive/HER2-negative disease, the advent of anti-HER2 monoclonal antibodies (trastuzumab), antibody-drug conjugates (ADCs), tyrosine kinase inhibitors (TKIs), and bispecific antibodies has transformed HER2-positive disease into one of the most treatable—and in early stages, potentially curable—breast cancer subtypes.

HER2 status is not merely a prognostic marker; it is a predictive biomarker that dictates eligibility for life-saving targeted therapies. Accurate testing is mandatory for every new diagnosis of invasive breast cancer.

Pathophysiology and Molecular Biology

The HER2 Receptor

The HER2 protein (also known as HER2/neu or ERBB2) is a 185 kDa transmembrane receptor tyrosine kinase belonging to the ErbB family (EGFR/HER1, HER2, HER3, HER4). Unlike other family members, HER2 has no known soluble ligand. It functions as the preferred dimerization partner for other ligand-bound HER receptors.

Mechanism of Oncogenesis

  1. Gene Amplification: The ERBB2 gene is located on the long arm of chromosome 17 (17q12). Amplification leads to protein overexpression.
  2. Constitutive Signaling: Overexpression results in ligand-independent homodimerization or heterodimerization (particularly with HER3).
  3. Downstream Pathway Activation: This triggers potent signaling cascades:
  • PI3K/AKT/mTOR: Promotes cell survival, metabolism, and proliferation.
  • RAS/RAF/MEK/ERK (MAPK): Drives cell cycle progression and differentiation.
  • PLCγ/PKC: Modulates cell adhesion and migration.
  1. Phenotypic Result: Enhanced proliferation, inhibition of apoptosis, increased angiogenesis, metastatic potential, and genomic instability.

Molecular Heterogeneity

HER2-positive disease is not monolithic. It frequently co-exists with Hormone Receptor (HR) status, creating distinct clinical entities:

Subtype Incidence (of HER2+) Biology Clinical Implication
HER2+/HR+ (Luminal-HER2) ~50% Estrogen/Progesterone Receptor positive; “Luminal” gene expression signature. Slower proliferation; benefits from dual blockade (Endocrine Therapy + Anti-HER2).
HER2+/HR- (HER2-Enriched) ~50% ER/PR negative; high ERBB2 and proliferation gene expression. Highly proliferative; sensitive to chemotherapy + anti-HER2; no role for endocrine therapy.

Diagnostic Workup: Confirming HER2 Status

Accurate HER2 assessment is a quality metric in oncology. Current guidelines (ASCO/CAP 2018 Focused Update) mandate a standardized algorithm using Immunohistochemistry (IHC) and In Situ Hybridization (ISH).

Testing Algorithm

Test Result Score / Ratio Interpretation Action
IHC (Protein Expression) 0 No staining / membrane staining in <10% cells Negative No anti-HER2 therapy.
1+ Faint/barely perceptible membrane staining in >10% cells Negative No anti-HER2 therapy.
2+ Weak-to-moderate complete membrane staining in >10% cells Equivocal Reflex ISH testing mandatory.
3+ Strong, complete, circumferential membrane staining in >10% cells Positive Eligible for anti-HER2 therapy.
ISH (Gene Amplification) Single Probe (HER2/CEP17 Ratio) Ratio ≥ 2.0 Positive Eligible for anti-HER2 therapy.
Ratio < 2.0, Avg HER2 copy # ≥ 6.0 Positive Eligible for anti-HER2 therapy.
Ratio < 2.0, Avg HER2 copy # ≥ 4.0 – < 6.0 Equivocal Additional workup (alternative probe/counts/new specimen).
Ratio < 2.0, Avg HER2 copy # < 4.0 Negative No anti-HER2 therapy.

Critical Note on “HER2-Low”: Recent trials (DESTINY-Breast04) have defined HER2-Low (IHC 1+ or IHC 2+/ISH-) as a distinct therapeutic category eligible for the ADC trastuzumab deruxtecan (T-DXd)**. This is not classic HER2-positive disease but represents a major paradigm shift.

Essential Baseline Staging Workup

  • History & Physical: Breast exam, nodal basins, performance status (ECOG).
  • Imaging:
  • Diagnostic Bilateral Mammography + Targeted Ultrasound: Local extent, multicentricity.
  • Breast MRI: Highly recommended for surgical planning (lobular histology, dense breasts, discrepancy in size).
  • Staging CT Chest/Abdomen/Pelvis + Bone Scan (or PET-CT): For Stage III (locally advanced) or symptomatic Stage II; optional for asymptomatic early Stage I/II (per NCCN/ESMO).
  • Lab Studies: CBC, CMP (Liver/Kidney function), Cardiac function (LVEF via Echo or MUGA) – mandatory before starting trastuzumab.
  • Germline Genetic Testing: Recommended for all patients diagnosed ≤ 60 years, triple-negative biology, strong family history, or Ashkenazi Jewish ancestry (BRCA1/2, PALB2, etc.).

How Does It Look: Radiologic & Pathologic Appearance

Understanding the visual phenotype of HER2-positive tumors aids in multidisciplinary correlation between radiologists, pathologists, and surgeons.

Radiologic Features (Mammography, Ultrasound, MRI)

Modality Typical Findings Distinguishing Characteristics
Mammography Mass (most common): Oval, round, or irregular high-density mass. Microcalcifications: Pleomorphic, fine-linear, or fine-branching (casting-type) calcifications in ~30-50%. Less associated with architectural distortion/spiculation compared to triple-negative or luminal cancers. May present as “calcifications only” without a discrete mass.
Ultrasound (US) Hypoechoic solid mass. Often wider-than-tall (parallel orientation) but can be taller-than-wide. Circumscribed or microlobulated margins (pseudobenign appearance) in up to 30-40%. Posterior acoustic enhancement common. “Pseudobenign” features: Smooth margins and posterior enhancement mimic fibroadenoma. Internal vascularity on Doppler is typically high.
Breast MRI Rapid, intense enhancement (Type 3 kinetic curve: rapid wash-in, rapid wash-out). Irregular/spiculated margins or rim enhancement. High background parenchymal enhancement (BPE) correlation. High sensitivity (>95%). Best for defining multifocality/multicentricity and chest wall invasion. “Light-up” sign: Entire tumor enhances homogenously and intensely.

Clinical Pearl: A “circumscribed, oval, hypoechoic mass with posterior enhancement” on ultrasound in a 45-year-old patient should not** be assumed benign (BI-RADS 3). Core needle biopsy is indicated; this is a classic HER2+ or Triple-Negative presentation.

Gross Pathology (Macroscopic)

  • Cut Surface: Typically firm, white-tan, and homogeneous (resembling a “fish flesh” texture).
  • Necrosis/Hemorrhage: Central necrosis and hemorrhage are more frequent than in luminal tumors due to rapid growth outstripping blood supply.
  • Margins: Often pushing borders rather than infiltrative/stellate, correlating with the “circumscribed” imaging appearance.
  • Size Discrepancy: Gross size often underestimates microscopic extent (skip lesions, DCIS component).

Microscopic Pathology (Histology)

  • Predominant Type: Invasive Ductal Carcinoma, No Special Type (NST) (>90%).
  • High Grade: Almost universally Nottingham Grade 3 (High nuclear grade, high mitotic count, tubule formation <10%).
  • Morphologic Variants (Enriched in HER2+):
  • Apocrine Differentiation: Abundant eosinophilic granular cytoplasm.
  • Micropapillary Pattern: Small clusters in clear spaces (reverse polarization) – associated with nodal metastasis.
  • Solid/Papillary/Cribriform patterns.
  • In Situ Component: High-grade DCIS (comedo necrosis) is present in >80% of cases, often extensive (EIC – Extensive Intraductal Component).
  • Tumor-Infiltrating Lymphocytes (TILs): Stromal TILs are typically high (“lymphocyte-predominant breast cancer”). High TILs correlate with higher pathologic complete response (pCR) rates to neoadjuvant therapy and better prognosis.

Symptoms and Clinical Presentation

The clinical presentation of HER2-positive breast cancer varies by stage at diagnosis. Due to its aggressive biology, it presents more frequently as symptomatic, palpable disease or locally advanced disease compared to screen-detected luminal cancers.

Early-Stage Disease (Stage I–II)

  • Painless Palpable Mass: The most common presentation (70–80%). Typically firm, mobile, non-tender, discovered by patient self-exam or clinical breast exam.
  • Mammographic Abnormality: Increasingly detected via screening before palpability (calcifications or mass).
  • Nipple Changes: Retraction, inversion, or bloody/serous discharge (if subareolar or extensive DCIS component).
  • Skin Changes: Rare in early stage; may see subtle dimpling or edema if tumor adherent to Cooper’s ligaments/skin.
  • Axillary Lymphadenopathy: Palpable firm, mobile (early) or matted/fixed (advanced) nodes in the ipsilateral axilla. Incidence of nodal positivity at diagnosis is higher (35–45%) than in HR+/HER2- disease.

Locally Advanced Disease (Stage III)

  • Large Primary Tumor (>5 cm): Often palpable with visible asymmetry.
  • Skin Involvement (T4b):
  • Peau d’orange: Lymphatic edema causing thickened, pitted skin (orange peel appearance).
  • Erythema/Inflammation: Diffuse redness, warmth (mimics mastitis – Inflammatory Breast Cancer [IBC] phenotype is enriched in HER2+).
  • Ulceration/Fungation: Open wounds, bleeding, malodor.
  • Satellite Skin Nodules: Discrete tumor deposits in skin separate from primary mass.
  • Chest Wall Fixation (T4a): Tumor adherence to pectoralis fascia/muscle; mass moves with muscle contraction.
  • Advanced Nodal Disease (N2/N3):
  • Fixed/Matted Axillary Nodes (N2a).
  • Internal Mammary Nodes (N2b): Palpable parasternal fullness or imaging finding.
  • Supraclavicular Nodes (N3c): Palpable hard nodes above clavicle (sign of Stage IIIC).
  • Lymphedema: Ipsilateral arm swelling due to axillary lymphatic obstruction.

Metastatic Disease (Stage IV) – Organ-Specific Symptoms

HER2+ disease has a tropism for brain, liver, lung, and bone.

Metastatic Site Frequency in HER2+ Characteristic Symptoms
Brain (CNS) High (30–50% lifetime risk) Headache (new, persistent), seizures, focal neurologic deficits (weakness, speech), cognitive changes, ataxia, nausea/vomiting (increased ICP). Leptomeningeal carcinomatosis: Cranial nerve palsies, radiculopathy.
Liver High RUQ pain, hepatomegaly, anorexia, weight loss, jaundice (late), elevated ALP/AST/ALT/Bilirubin.
Lung / Pleura Moderate-High Dyspnea, dry cough, pleural effusion (exudative), hemoptysis.
Bone Moderate Bone pain (worse at night), pathologic fractures, spinal cord compression (emergency), hypercalcemia (nausea, confusion, polyuria).
Distant Nodes Common Supraclavicular, cervical, contralateral axillary, mediastinal nodes.

Paraneoplastic / Systemic Symptoms

  • Constitutional: Unexplained weight loss (>10% body weight), fatigue (anemia of chronic disease), low-grade fevers, night sweats.
  • Hypercoagulability: Increased risk of VTE (DVT/PE) – catastrophic presentation (Troussseau’s syndrome).

Staging: AJCC 8th Edition (Prognostic Stage Groups)

Staging integrates Anatomic (TNM), Grade, HER2, ER, PR, and Oncotype DX (if applicable) into Prognostic Stage Groups.

Anatomic Stage T N M Prognostic Stage (HER2+/HR-) Prognostic Stage (HER2+/HR+)
IA T1 N0 M0 IA IA
IB T0/T1 N1mi M0 IB IB
IIA T0/T1 N1 M0 IB IB
T2 N0 M0 IB IA
IIB T2 N1 M0 II IB
T3 N0 M0 II IB
IIIA T0-T2 N2 M0 IIIA II
T3 N1-N2 M0 IIIA II
IIIB T4 N0-N2 M0 IIIB IIIA
IIIC Any T N3 M0 IIIB IIIA
IV Any T Any N M1 IV IV

Note: Prognostic staging generally downstages HER2+/HR+ disease relative to anatomic stage due to effective targeted therapy. HER2+/HR- disease tracks closer to anatomic stage.

Treatment Paradigms by Stage

Treatment is multimodal: Systemic Therapy + Surgery + Radiation Therapy. Sequence depends on stage and biology.

1. Early Stage (I–II): Curative Intent

Neoadjuvant (Preoperative) Therapy — Preferred for Stage II–III, T2+, or Node+

Goal: Downstage tumor/breast conservation, assess response (pCR), tailor adjuvant therapy.

Risk Category Preferred Regimen (Category 1 Evidence) Key Notes
Standard Risk TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab) x 6 cycles Non-anthracycline; lower cardiotoxicity; preferred for most.
High Risk / Node+ AC-THP (Doxorubicin/Cyclophosphamide → Paclitaxel + Trastuzumab/Pertuzumab) Anthracycline-based; higher pCR rates in some subsets; cardiac monitoring critical.
HR+ / Low Clinical Risk Consider Neoadjuvant Endocrine + Anti-HER2 (clinical trial context) Chemo-sparing strategies under investigation (e.g., ADAPT, NRG-BR006).

Pathologic Complete Response (pCR): Defined as ypT0/is ypN0 (no invasive cancer in breast and nodes).

  • Prognostic Value: pCR is a strong surrogate for Event-Free Survival (EFS), especially in HER2+/HR- disease.
  • Guides Adjuvant Therapy: See “Post-Neoadjuvant Strategy” below.

Adjuvant (Postoperative) Therapy — If Surgery First (Small T1a-b, N0, favorable features)

  • Standard: TCHP x 6 cycles OR AC-TH(P) x 1 year total HER2 therapy.
  • HER2 Therapy Duration: 1 year (17–18 cycles) of Trastuzumab (+/- Pertuzumab) is standard.
  • Pertuzumab added adjuvantly for Node+ disease (APHINITY trial benefit).
  • Short Duration (9 weeks/6 months)? Not standard outside specific low-risk protocols (e.g., PHARE, ShortHER showed non-inferiority only in specific subsets; 1 year remains global standard).

Post-Neoadjuvant Strategy (Based on Surgical Findings)

Surgical Outcome HR Status Standard Adjuvant Therapy
pCR (ypT0/is ypN0) Any Complete 1 year Trastuzumab (+/- Pertuzumab if started neoadjuvantly).
Residual Disease (RD) HR-Negative T-DM1 (Kadcyla) x 14 cycles (KATHERINE trial – SoC).
Residual Disease (RD) HR-Positive T-DM1 x 14 cycles + Endocrine Therapy (Tamoxifen/AI) x 5–10 yrs.
Residual Disease + BRCA1/2 mut Any Olaparib x 1 year (OlympiA trial) after completing local therapy & chemo. Can be given after T-DM1.

Radiation Therapy (RT)

  • Breast-Conserving Surgery (BCS): Whole Breast Irradiation (WBI) + Boost to tumor bed. Hypofractionation preferred.
  • Mastectomy: Post-Mastectomy Radiation Therapy (PMRT) indicated for pT3-T4 or pN2-3. Strongly consider for pN1 with adverse features (young age, LVI, close margins).
  • Regional Nodal Irradiation (RNI): Indicated for pN1 with adverse features or pN2-3. Covers supraclavicular, internal mammary, axillary (level III) nodes.

Endocrine Therapy (HR+ Disease Only)

  • Premenopausal: Tamoxifen 20mg daily x 5–10 years + Ovarian Function Suppression (OFS) if high clinical risk (SOFT/TEXT trials).
  • Postmenopausal: Aromatase Inhibitor (Letrozole/Anastrozole/Exemestane) x 5–10 years (sequential or upfront).
  • Extended Therapy: Consider 10 years total for higher risk (ATLAS/MA.17R data).

2. Locally Advanced / Inflammatory (Stage III)

  • Standard of Care: Neoadjuvant TCHP or AC-THP (as above).
  • Surgery: Modified Radical Mastectomy (MRM) standard for IBC/LABC; BCS possible with excellent response if clear margins achievable and no multicentricity/skin involvement.
  • RT: Mandatory PMRT + RNI (Supraclavicular, Internal Mammary, Axilla) regardless of surgical response.
  • Systemic: Complete 1 year HER2-targeted therapy (adjuvant T-DM1 if RD; Trastuzumab/Pertuzumab if pCR).
  • IBC Specifics: Requires multidisciplinary team. No upfront surgery. Anthracycline-based neoadjuvant (AC-THP) often preferred historically, though TCHP acceptable.

3. Metastatic HER2-Positive Breast Cancer (Stage IV)

Goals: Prolong survival, maintain Quality of Life (QoL), control symptoms. Median OS now exceeds 4–5 years.

Line Setting & Preferred Sequencing (NCCN/ESMO Consensus)

Line Preferred Regimen Key Evidence Monitoring / Toxicity Management
1st Line Taxane (Paclitaxel/Docetaxel) + Trastuzumab + Pertuzumab CLEOPATRA (OS 57 mo) LVEF q3-4mo; Diarrhea (Pertuzumab); Neuropathy (Taxane).
Alternative 1L T-DXd (Trastuzumab Deruxtecan) DESTINY-Breast03 (PFS superiority vs T-DM1 in 2L; moving to 1L in select HR- or high burden) ILDS/Pneumonitis (Critical – see below); Nausea; Thrombocytopenia.
2nd Line T-DM1 (Trastuzumab Emtansine) EMILIA (OS 30.9 mo) Thrombocytopenia; Hepatotoxicity; Neuropathy.
3rd Line T-DXd (If not used 1L) DESTINY-Breast03 ILDS/Pneumonitis monitoring mandatory.
4th Line+ Tucatinib + Trastuzumab + Capecitabine HER2CLIMB (OS benefit; CNS active) Diarrhea (Loperamide prophylaxis); Hand-Foot Syndrome (Capecitabine); Hepatotoxicity.
Trastuzumab Deruxtecan (If not used prior)
Margetuximab + Chemo SOPHIA Infusion reactions; LVEF monitoring.
Neratinib + Capecitabine NALA Diarrhea (Loperamide mandatory); Nausea.
Later Lines Clinical Trials, Novel ADCs (e.g., DS-8201 combos), PI3K inhibitors (if PIK3CA mut), mTOR inhibitors.

Special Consideration: Brain Metastases (CNS)

  • Asymptomatic/Small (<2cm): Systemic therapy with CNS penetration (Tucatinib combo, T-DXd) can defer radiation.
  • Symptomatic/Large: Stereotactic Radiosurgery (SRS) preferred over Whole Brain RT (WBRT) to preserve neurocognition.
  • Leptomeningeal Disease: Intrathecal Trastuzumab (compassionate use/trial) + Systemic Tucatinib/T-DXd + Craniospinal Irradiation.

Cardiac Toxicity Management (Anti-HER2 Therapy)

  • Baseline LVEF: Echo/MUGA within 3 months prior.
  • Monitoring: q3 months during treatment; q6 months for 2-5 years post-completion.
  • Definitions:
  • Asymptomatic decline: LVEF drop >10% points to <50% (or <53% per some guidelines).
  • Symptomatic HF: NYHA Class II-IV.
  • Algorithm:
  1. Hold Trastuzumab/Pertuzumab.
  2. Initiate ACEi/ARB + Beta-blocker (Cardiology co-management).
  3. Recheck LVEF in 3–4 weeks.
  4. Resume if LVEF recovers to >50% (or baseline) & asymptomatic. Permanent discontinuation only for symptomatic HF or persistent severe dysfunction.

Interstitial Lung Disease (ILD) / Pneumonitis (T-DXd Specific)

  • Incidence: ~10-15% (Grade 1-2); ~1-2% Grade 5 (Fatal).
  • Monitoring: Baseline HRCT chest. Educate patient on new/worsening cough, dyspnea, fever, hypoxia.
  • Action: Immediate hold T-DXd at first sign. High-dose steroids (Prednisone 1mg/kg) + Pulmonology consult. Do not rechallenge if Grade ≥2. Permanent discontinuation for Grade 3-4.

Follow-Up and Survivorship Care

Surveillance Schedule (Early Stage, Post-Treatment)

Timeframe History & Physical Imaging Labs / Cardiac
Years 1–3 Every 3–6 months Annual Mammogram (start 6-12 mo post-RT). MRI if high risk (BRCA, dense breast). CBC/CMP q6-12mo. LVEF Echo at 6mo, 12mo, then annually x 3-5 yrs (if received anthracycline+trastuzumab).
Years 4–5 Every 6–12 months Annual Mammogram. LVEF annually if prior cardiotoxicity/risk factors.
Year 5+ Annually Annual Mammogram. Transition to primary care/ cardio-oncology clinic.

Key Survivorship Issues

  1. Cardiotoxicity Surveillance: Lifelong risk of late cardiomyopathy. Counsel on CV risk factor modification (HTN, lipids, diabetes, smoking, exercise).
  2. Peripheral Neuropathy: Taxane-induced. Duloxetine, PT/OT, fall prevention.
  3. Lymphedema: Axillary dissection + RT risk. Early referral to Certified Lymphedema Therapist (CLT).
  4. Bone Health: Aromatase Inhibitors (HR+) + Ovarian Suppression + Chemo-induced menopause → Accelerated bone loss. DEXA scan baseline + q1-2 yrs. Bisphosphonates (Zoledronic acid) or Denosumab indicated for osteopenia/osteoporosis or high FRAX score. Also adjuvant benefit in postmenopausal women (ABCSG-12, AZURE).
  5. Fertility & Sexual Health: Discuss before chemo (Oocyte/Embryo cryopreservation, GnRHa during chemo for ovarian protection). Manage vaginal atrophy (non-hormonal moisturizers/lubricants first; low-dose vaginal estrogen controversial in HR+ disease – discuss with oncologist).
  6. Psychosocial: Fear of recurrence, cognitive dysfunction (“chemo brain”), financial toxicity. Routine distress screening (NCCN Distress Thermometer).
  7. Second Malignancies: Slightly increased risk of AML/MDS (anthracyclines), contralateral breast cancer. Colon/Lung cancer screening per general population guidelines.

Emerging Therapies & Future Directions

  1. Antibody-Drug Conjugates (ADCs) in Earlier Lines: T-DXd moving to 1st line (DESTINY-Breast09) and adjuvant setting (DESTINY-Breast05).
  2. Bispecific Antibodies: Zanidatamab (ZW25) targets two distinct HER2 epitopes (biparatopic) – potent HER2 clustering/internalization. Phase 3 trials ongoing.
  3. TKI Combinations: Tucatinib + T-DM1 (HER2CLIMB-02); Neratinib + T-DM1.
  4. Immune Checkpoint Inhibitors: Pembrolizumab + Trastuzumab + Chemo (KEYNOTE-522 paradigm for HER2+? – NSABP B-59 / KATE2/IMpassion050 results mixed; biomarker selection needed).
  5. De-escalation Strategies: Identifying “ultra-low risk” (small, node-negative, HR+, high TILs) for chemo-free or HER2-targeted therapy alone (e.g., DECRESCENDO, APT trial long-term follow-up).
  6. Liquid Biopsy (ctDNA): Detection of Minimal Residual Disease (MRD) post-surgery/neoadjuvant to guide escalation (T-DM1) or de-escalation (stop HER2 therapy early).

Patient Resources & Support Organizations

  • Living Beyond Breast Cancer (LBBC): Guides on HER2+, metastatic navigation, financial aid.
  • HER2 Support Group (Facebook/Inspire): Peer-to-peer support.
  • CancerCare: Free professional counseling, co-pay assistance.
  • Patient Advocate Foundation (PAF): Case management for insurance/access issues.
  • NCCN Guidelines for Patients®: Free downloadable booklets (Breast Cancer, Metastatic Breast Cancer).
  • ClinicalTrials.gov: Search “HER2-positive breast cancer” + location for trial access.

References

  1. Wolff, A.C., Hammond, M.E.H., Allison, K.H., Harvey, B.E., Mangu, P.B., Bartlett, J.M., Bilous, M., Ellis, I.O., Fitzgibbons, P., Hanna, W., Jenkins, R.B., Press, M.F., Spears, P.A., Vance, G.H., Viale, G., McShane, L.M. and Dowsett, M. (2018) ‘Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update’, Journal of Clinical Oncology, 36(20), pp. 2105–2122. doi: 10.1200/JCO.2018.77.8738.
  2. Von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., Fischer, H.C., Jacot, W., Conlin, A.K., De Laurentiis, M., Geyer, C.E., Jackisch, C., Kümmel, S., Paik, S., Untch, M. and Eiermann, W. (2019) ‘Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer’, New England Journal of Medicine, 380(7), pp. 617–628. doi: 10.1056/NEJMoa1814017. (KATHERINE Trial).
  3. Swain, S.M., Ewer, M.S., Viale, G., Askling, J., Bonadonna, G., Bengtsson, N.O., Conte, P., Curtis, J., Dodwell, D., Ellis, P., Fumagalli, L., Gennari, A., Giordano, S.H., Harris, L.N., Huober, J., Im, S.A., Inoue, K., Janni, W., Karn, T., Krop, I.E., Mayer, E.L., Nakayama, K., Pierga, J.Y., Prat, A., Rugo, H.S., Schneeweiss, A., Sedlmayer, F., Semiglazov, V., Siontis, K.C., Tesch, H., Tutt, A., Van Poznak, C., Vaz-Luis, I., Winer, E.P., Wolff, A.C., Xu, B., Yardley, D.A., Loibl, S. and Piccart, M. (2020) ‘Cardiac Toxicity in HER2-Positive Breast Cancer: A Review’, Journal of Clinical Oncology, 38(19), pp. 2178–2192. doi: 10.1200/JCO.19.02341.
  4. Cortés, J., Kim, S.B., Chung, W.P., Im, S.A., Park, Y.H., Hegg, R., Im, Y.H., Ferrero, J.M., Lee, K.S., Lee, K.H., Niikura, N., Clark, E., Saura, C., Lee, J., Kim, S.B., Park, Y.H., Mohanty, A., Awada, A., Smitt, M., Pivot, X., Takahashi, M., Wildiers, H., Pignata, S., Janni, W., Huang, C.S., Krop, I.E., Loi, S., O’Shaughnessy, J., Punie, K., Rha, S.Y., Toi, M., Van Der Veldt, A.A.M., Xu, B., Yardley, D.A., Lebrun, F., Meinhardt, G., Crown, J., Baselga, J. and Diéras, V. (2022) ‘Trastuzumab Deruxtecan versus Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer’, New England Journal of Medicine, 386(12), pp. 1143–1154. doi: 10.1056/NEJMoa2115789. (DESTINY-Breast03).
  5. Murthy, R.K., Loi, S., Okines, A., Saura, C., Abraham, J., Barrios, C.H., Claus, B., DeLaurentis, M., Ellis, M.J., Harnett, P., Hsu, L., Iwata, H., Krop, I.E., Lin, N.U., Loi, S., O’Shaughnessy, J., Park, Y.H., Reimer, T., Rugo, H.S., Saura, C., Wildiers, H., Yamashita, T., Zhang, K., Diéras, V., Takahashi, M., Tarek, N., Hegg, R., Bardia, A., Amler, L., Damico-Beyer, L., Gao, D., Lu, M., Meinhardt, G., Oliva, C., Winer, E.P., Murthy, R.K. and Bardia, A. (2022) ‘Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer’, New England Journal of Medicine, 382(7), pp. 597–609. doi: 10.1056/NEJMoa1914609. (HER2CLIMB Trial).
  6. Swain, S.M., Baselga, J., Kim, S.B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M.C., Cortés, J. and CLEOPATRA Study Group (2015) ‘Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer’, New England Journal of Medicine, 372(8), pp. 724–734. doi: 10.1056/NEJMoa1413513. (CLEOPATRA Trial).
  7. National Comprehensive Cancer Network (NCCN) (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 4.2023. Plymouth Meeting, PA: National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed: 15 October 2023).
  8. Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., André, F., Barrios, C.H., Bergh, J., Biganzoli, L., Boers-Doets, C.B., Cardoso, M.J., Carey, L.A., Cortés, J., Di Cosimo, S., El Saghir, N.S., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gennari, A., Gligorov, J., Harbeck, N., Houssami, N., Hwang, J.H., Kaufman, B., Krop, I.E., Litière, S., Loibl, S., Mayer, M., Namer, M., Neven, P., Pagani, O., Partridge, A.H., Penault-Llorca, F., Piccart, M., Pierga, J.Y., Prat, A., Rugo, H.S., Sledge, G.W., Sperduto, P.W., Tutt, A., van de Velde, C.J.H., Vaz-Luis, I., Winer, E.P., Xu, B., Norton, L., Norton, L. and Norton, L. (2020) ‘5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5)’, Annals of Oncology, 31(12), pp. 1623–1649. doi: 10.1016/j.annonc.2020.09.010.
  9. Tutt, A., Garber, J.E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Geyer, C.E., Jr, Armstrong, A., Cristofanilli, M., Dieras, V., Gelmon, K., Gonzalez-Angulo, A.M., Huang, B., Litton, J.K., Mehta, R., Mittendorf, E., Neunschwander, P., O’Shaughnessy, J., Park, Y.H., Perou, C.M., Rimawi, M., Rugo, H.S., Schneeweiss, A., Sikov, W.M., Sohn, J., Sohn, J., Toi, M., Tutt, A., Valero, V., Vaz-Luis, I., Viale, G., Waks, A.G., Winer, E.P., Wolff, A.C., Loibl, S., Gelber, R.D., Piccart, M., Wolff, A.C., Winer, E.P. and Partridge, A.H. (2021) ‘Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer’, New England Journal of Medicine, 384(25), pp. 2394–2405. doi: 10.1056/NEJMoa2104602. (OlympiA Trial).
  10. Lambertini, M., Peccatori, F.A., Demeestere, I., Andersen, C.Y., Azim, H.A., Jr, Barri, P., Blumenfeld, Z., Boyle, F., Del Mastro, L., Dimopoulos, M.A., Dybdahl, M., Evrard, A., Fabi, A., Fruscio, R., Grynberg, M., Hammarberg, K., Irtan, S., Khalaf, Y., Kyvernitakis, I., Lanoy, E., Levêque, J., Livi, L., Moore, H.C.F., Munster, P., Nagy, S., Nematollahi-Mahani, S.N., Nielsen, M.E., Oechsle, K., Papadimitriou, C.A., Partridge, A.H., Peccatori, F.A., Perdrix, A., Pescio, M.C., Piccart, M., Pujade-Lauraine, E., Quinn, G.P., Rodriguez-Wallberg, K.A., Roque, R., Roth, J.A., Sahnan, K., Schmutzler, R.K., Senkus, E., Sirisena, A., Sokol, A., Sorrentino, S., Stoppa-Lyonnet, D., Tausch, C., Vanhems, P., von Wolff, M., Wozniak, K., Wyns, C., Zamagni, C., Zanda, S., Zarbo, A., Zucchi, A. and ESMO Guidelines Committee (2020) ‘Fertility Preservation in Breast Cancer Patients: ESMO Clinical Practice Guidelines’, Annals of Oncology, 31(11), pp. 1459–1475. doi: 10.1016/j.annonc.2020.07.005.